UBS Group’s Forte Biosciences FBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.5M | Buy |
164,557
+144,107
| +705% | +$3.42M | ﹤0.01% | 4539 |
|
|
2026
Q1 | $530K | Sell |
20,450
-4,374
| -18% | -$126K | ﹤0.01% | 6044 |
|
|
2025
Q4 | $677K | Buy |
24,824
+23,264
| +1,491% | +$408K | ﹤0.01% | 5888 |
|
|
2025
Q3 | $23.4K | Buy |
1,560
+1,559
| +155,900% | +$18K | ﹤0.01% | 8054 |
|
|
2025
Q2 | $13 | Sell |
1
-526
| -100% | -$4.53K | ﹤0.01% | 10139 |
|
|
2025
Q1 | $4.09K | Buy |
+527
| New | +$6.22K | ﹤0.01% | 9148 |
|
|
2024
Q4 | – | Sell |
-1,606
| Closed | -$8.98K | – | 10057 |
|
|
2024
Q3 | $8.98K | Buy |
1,606
+634
| +65% | +$6.52K | ﹤0.01% | 7812 |
|
|
2024
Q2 | $13.1K | Buy |
972
+971
| +97,100% | +$15.7K | ﹤0.01% | 7568 |
|
|
2024
Q1 | $23 | Sell |
1
-5
| -83% | -$87 | ﹤0.01% | 9019 |
|
|
2023
Q4 | $120 | Sell |
6
-93
| -94% | -$1.3K | ﹤0.01% | 8898 |
|
|
2023
Q3 | $1.64K | Buy |
99
+98
| +9,800% | +$2.17K | ﹤0.01% | 7877 |
|
|
2023
Q2 | $34 | Sell |
1
-380
| -100% | -$9.87K | ﹤0.01% | 8644 |
|
|
2023
Q1 | $9.62K | Buy |
381
+312
| +452% | +$7.85K | ﹤0.01% | 7640 |
|
|
2022
Q4 | $1.72K | Buy |
69
+68
| +6,800% | +$1.74K | ﹤0.01% | 9808 |
|
|
2022
Q3 | $0 | Sell |
1
-75
| -99% | -$2.38K | ﹤0.01% | 10499 |
|
|
2022
Q2 | $2K | Sell |
76
-11
| -13% | -$349 | ﹤0.01% | 9542 |
|
|
2022
Q1 | $3K | Sell |
87
-374
| -81% | -$14.2K | ﹤0.01% | 9437 |
|
|
2021
Q4 | $25K | Buy |
461
+449
| +3,742% | +$30.2K | ﹤0.01% | 7581 |
|
|
2021
Q3 | $1K | Sell |
12
-13
| -52% | -$7.2K | ﹤0.01% | 9176 |
|
|
2021
Q2 | $21K | Buy |
25
+13
| +108% | +$11.7K | ﹤0.01% | 7276 |
|
|
2021
Q1 | $10K | Sell |
12
-16
| -57% | -$13.1K | ﹤0.01% | 7919 |
|
|
2020
Q4 | $26K | Buy |
28
+1
| +4% | +$940 | ﹤0.01% | 6746 |
|
|
2020
Q3 | $34K | Buy |
+27
| New | +$17.9K | ﹤0.01% | 5908 |
|
|
2020
Q2 | – | Sell |
-56
| Closed | -$26K | – | 8053 |
|
|
2020
Q1 | $26K | Sell |
56
-48
| -46% | -$18.8K | ﹤0.01% | 6322 |
|
|
2019
Q4 | $21K | Buy |
104
+60
| +136% | +$13.6K | ﹤0.01% | 6841 |
|
|
2019
Q3 | $11K | Buy |
44
+24
| +120% | +$36.4K | ﹤0.01% | 7096 |
|
|
2019
Q2 | $50K | Buy |
20
+4
| +25% | +$11.9K | ﹤0.01% | 5926 |
|
|
2019
Q1 | $67K | Sell |
16
-18
| -53% | -$69.5K | ﹤0.01% | 5343 |
|
|
2018
Q4 | $105K | Buy |
34
+6
| +21% | +$25.8K | ﹤0.01% | 5498 |
|
|
2018
Q3 | $162K | Buy |
28
+9
| +47% | +$34.3K | ﹤0.01% | 5217 |
|
|
2018
Q2 | $66K | Hold |
19
| – | – | ﹤0.01% | 5772 |
|
|
2018
Q1 | $85K | Buy |
+19
| New | +$88K | ﹤0.01% | 5330 |
|
|
2017
Q4 | – | Sell |
-1
| Closed | -$3K | – | 7917 |
|
|
2017
Q3 | $3K | Sell |
1
-3
| -75% | -$13.4K | ﹤0.01% | 7390 |
|
|
2017
Q2 | $17K | Buy |
+4
| New | +$22.5K | ﹤0.01% | 6407 |
|
Other funds holding FBRX
AAA
VCM
WP
IHAM
CS
UBS Group's FBRX Position: Q2 2026 in Review
UBS Group increased its Forte Biosciences (FBRX) stake by 705% in Q2 2026, buying an estimated $3.42M and bringing the position to 164,557 shares worth $3.5M. The position accounts for ﹤0.01% of the portfolio, ranked #4539.
UBS Group first reported a position in FBRX in Q2 2017 and has held it in 34 quarters since. 57 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.
- UBS Group held 164,557 shares of Forte Biosciences worth $3.5M as of Q2 2026.
- UBS Group bought 144,107 Forte Biosciences shares in Q2 2026, an estimated $3.42M.
- Forte Biosciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4539 holding.
- UBS Group first reported a position in Forte Biosciences in Q2 2017 and has held it in 34 quarters since.
- 57 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.